10 Best Pharma Stocks to Buy for Long Term Growth

3. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 88 

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Numerous therapeutic classes, such as hematology, oncology, cardiology, immunology, and neuroscience, are represented among its medications.

Due to its collaborations and acquisitions, Bristol-Myers Squibb Company (NYSE:BMY) has a strong pipeline and a strong medicine portfolio, which together provide a broad economic moat. For example, its pipeline was reinforced by the acquisition of Celgene, giving it a solid foothold in the blood cancer market. The recent acquisitions of neurology company Karuna and cancer companies RayzeBio and Mirati by the company have strengthened the company’s pipeline overall.

Bristol-Myers Squibb Company (NYSE:BMY) has also demonstrated impressive dividend growth, outpacing the sector median of two years by 300%. The company has paid regular dividends for 93 consecutive years while maintaining a 16-year streak of dividend growth. This illustrates the business’s sound financial standing and capacity to provide value to investors.